One-Liner
A consumer-facing service analyzing FDA adverse event reports to help patients make more informed drug choices — killed because the revenue model was unclear and regulatory constraints limit actionable output.
AI Thinking Process
FDA FAERS adverse event database is public but hard to interpret. Consumer-facing analysis layer: 'before you start this medication, here are the 500 adverse events reported.'
Who pays? Consumers don't pay for health data tools. Pharma won't pay for a tool that highlights their drug's problems. FDA won't pay for consumer education. Revenue model is empty.
Killed: revenue model unclear. Public health data tools consistently fail on monetization.
Kill Reason
The FDA FAERS database is public and already analyzed by multiple academic and consumer health tools. The product's differentiation would need to be clinical interpretation of adverse events — which requires medical supervision to publish actionable advice without running into FDA's off-label promotion rules. Revenue model is unclear: consumers don't pay for health data tools at sustainable ARPU, and pharma companies would not pay for a tool that highlights their drug's adverse events.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: The accuracy cliff is fatal: even with careful 'match not authenticate' framing, a wrong call on pharmaceutical safety has catastrophic liability exposure. Sproxil, the African drug authentication leader, has no LatAm presence — but their natural LatAm expansion would eliminate the market gap in 12-24 months. Consumer freemium unit economics are too weak to sustain the accuracy investment required.
killed: FEATURE gate killed it in Pass 2. Every major biologic drug manufacturer launches a branded patient-support app alongside PDUFA approval (BiogenLink for MS, MyOcrevus for Ocrevus, Complete for Humira for arthritis). Eisai/Biogen will almost certainly launch a LEQEMBI patient-support app at the August 24 approval event. An independent app loses the primary acquisition channel — physicians and specialty pharmacies push the branded app — and cannot close the acquisition-cost math against a free branded competitor.
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.